| Drug Name |
Canagliflozin |
| Drug ID |
BADD_D00344 |
| Description |
Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label].
It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus [L5897], [FDA label].
Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes [L5897]. Cardiovascular disease is the most common cause of death in these patients [A177083]. |
| Indications and Usage |
Canagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Use in type 1 diabetes mellitus patients or in treatment of diabetic ketoacidosis is not recommended. |
| Marketing Status |
Prescription |
| ATC Code |
A10BK02 |
| DrugBank ID |
DB08907
|
| KEGG ID |
D09592
|
| MeSH ID |
D000068896
|
| PubChem ID |
24812758
|
| TTD Drug ID |
D08DFX
|
| NDC Product Code |
50090-5034; 55154-1425; 50090-5029; 70966-0001; 12578-615; 50923-1216; 50458-141; 55111-978; 50458-140; 42385-735; 17314-575; 59651-065; 50090-4364; 46708-886; 14445-017; 17314-577; 12578-611; 55154-1426; 50090-5033 |
| Synonyms |
Canagliflozin | Invokana | Canagliflozin Hemihydrate | Canagliflozin, Anhydrous | 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene - T777973 |
